Valuation: Aligos Therapeutics, Inc.

Market Cap 31.54M 27.48M 26M 23.61M 44.11M 3.02B 44.35M 309M 120M 1.54B 118M 116M 4.92B P/E 2026 *
-0.8x
P/E 2027 * -0.96x
Enterprise Value -2.07M -1.8M -1.71M -1.55M -2.9M -199M -2.91M -20.32M -7.86M -101M -7.78M -7.61M -323M EV / Sales 2026 *
-0.06x
EV / Sales 2027 * -57.3x
Free-Float
77.91%
Yield 2026 *
-
Yield 2027 * -
1 day+2.38%
1 week-6.00%
Current month-11.77%
1 month-24.96%
3 months+3.61%
6 months-33.03%
Current year-44.53%
1 week 4.82
Extreme 4.82
5.5
1 month 4.82
Extreme 4.82
7.72
Current year 3.98
Extreme 3.98
10.49
1 year 3.98
Extreme 3.98
13.69
3 years 3.76
Extreme 3.76
46.8
5 years 3.76
Extreme 3.76
449.25
10 years 3.76
Extreme 3.76
937.75
Manager TitleAgeSince
Chief Executive Officer 64 2018-02-04
Director of Finance/CFO 60 2020-05-31
Chief Tech/Sci/R&D Officer 65 2018-04-30
Director TitleAgeSince
Director/Board Member 64 2018-07-31
Director/Board Member 74 2018-07-31
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap. Importance
3/9/26 Free

Chief Technology Officer

23,310 0.4354%
3/9/26 Free

Controller/Auditor

9,450 0.1765%
3/9/26 Free

Chief Executive Officer

105,840 1.9770%
Change 5-day change 1-year change 3-year change Capi.($)
+2.38%-6.00%-42.23%-74.15% 31.54M
+1.23%+1.30%-0.69%+9.57% 45.91B
+0.23%+4.85%+44.23%+27.27% 44.25B
+0.52%-5.17%+340.58%+520.09% 41.99B
+1.55%+0.70%+8.03%+76.45% 39.58B
+1.75%-1.53%+12.22%+41.11% 31.08B
-0.20%+4.93%+25.35%+119.72% 17.21B
-3.49%-8.35% - - 16.27B
+2.92%+8.37%+22.73%+38.87% 14.96B
-2.45%+6.38%-1.99%-35.16% 13.42B
Average +0.44%+0.56%+45.36%+80.42% 26.47B
Weighted average by Cap. +0.59%+0.68%+71.14%+120.58%

Financials

2026 *2027 *
Net sales 35.99M 31.36M 29.67M 26.94M 50.35M 3.45B 50.62M 353M 137M 1.75B 135M 132M 5.61B 4.65M 4.05M 3.83M 3.48M 6.5M 446M 6.54M 45.63M 17.64M 227M 17.46M 17.08M 725M
Net income -79.34M -69.13M -65.41M -59.39M -111M -7.61B -112M -779M -301M -3.87B -298M -291M -12.37B -125M -109M -103M -93.49M -175M -11.98B -176M -1.23B -474M -6.08B -469M -459M -19.47B
Net Debt -33.61M -29.28M -27.7M -25.16M -47.01M -3.22B -47.27M -330M -128M -1.64B -126M -123M -5.24B -298M -260M -246M -223M -417M -28.6B -419M -2.93B -1.13B -14.53B -1.12B -1.1B -46.5B
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
26-09-17 US$5.170 +2.38% 21,703
26-09-16 US$5.050 +1.20% 41,651
26-09-15 US$4.990 -0.99% 34,487
26-09-14 US$5.040 -3.45% 28,021
26-09-11 US$5.220 -2.06% 37,043
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.170USD
Average target price
52.38USD
Spread / Average Target
+913.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALGS Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!